BACKGROUND: Proteinase-activated receptor 2 (PAR-2) is a G-protein coupled transmembrane receptor activated by trypsin by site-specific cleavage. Its presence on pancreatic structures was demonstrated in the past. PAR-2 physiologically involves in duct/acinary cells secretion, arterial tonus regulation or capillary liquid turnover. During development of acute pancreatitis/acute pancreatic lesion (APL) these mentioned structures are influenced by very high concentration of trypsin due to its increased basolateral secretion into the interstitium. The aim of our study as presented was to investigate whether PAR-2 is also involved in APL following changes of PAR-2 expression. METHODS: APL was investigated in Wistar rats after injection of 0.1 mL taurocholate into the ductus choledochus. Anatomy, histology, reverse transcriptase polymerase chain reaction (RT PCR) as well as immunohistochemistry and Western-blot analysis of pancreatic tissue were performed using antibody mapping of the new NH2 terminal of PAR-2 after trypsin cleavage. Results from control rats and d 1 or d 4 rats after taurocholate injection were compared. RESULTS: Much higher positivity on acinary/duct cells was observed in APL induced animals than in controls. Similar findings were noticed on arterial smooth muscle cells. Surprisingly, parallel to the exocrine pancreas and vessel findings, enhanced Langerhans' islet cell positivity was observed in experimental animals. CONCLUSIONS: Based on these results, we have demonstrated that during APL development PAR-2 expression increases. This effect is caused by conformational changes after PAR-2 activation, and the new NH2 terminal of activated receptor presentation. We suggest that PAR-2 physiological functions are enhanced during APL development.

Institute of Biophysics 1st Medical School Charles University Prague Czech Republic

Zobrazit více v PubMed

Br J Pharmacol. 1998 Oct;125(4):591-4 PubMed

Br J Pharmacol. 1998 Oct;125(3):419-22 PubMed

J Int Med Res. 1996 Jan-Feb;24(1):59-68 PubMed

Pharmacol Rev. 2001 Jun;53(2):245-82 PubMed

Br J Pharmacol. 2000 Apr;129(8):1808-14 PubMed

Biochem J. 1996 Mar 15;314 ( Pt 3):1009-16 PubMed

Scand J Gastroenterol Suppl. 1996;219:1-5 PubMed

Biosci Biotechnol Biochem. 2000 Aug;64(8):1553-62 PubMed

Am J Physiol Lung Cell Mol Physiol. 2000 Jan;278(1):L193-201 PubMed

J Cell Sci. 2000 Sep;113 ( Pt 17):3093-101 PubMed

Scand J Gastroenterol Suppl. 1996;219:10-5 PubMed

Br J Surg. 1996 Jul;83(7):919-23 PubMed

Gastroenterology. 2000 Nov;119(5):1324-32 PubMed

Circulation. 1999 May 18;99(19):2590-7 PubMed

Eur J Biochem. 1995 Aug 15;232(1):84-9 PubMed

Scand J Gastroenterol Suppl. 1996;219:37-42 PubMed

J Am Soc Nephrol. 2000 Jun;11(6):1016-25 PubMed

J Clin Invest. 1999 Jan;103(2):261-9 PubMed

Proc Natl Acad Sci U S A. 1997 Aug 5;94(16):8884-9 PubMed

Int J Pancreatol. 1998 Oct;24(2):97-102 PubMed

Scand J Gastroenterol Suppl. 1996;219:32-6 PubMed

Biotech Histochem. 2000 Mar;75(2):85-90 PubMed

Can J Physiol Pharmacol. 1998 Jan;76(1):16-25 PubMed

Scand J Gastroenterol Suppl. 1996;219:6-9 PubMed

FASEB J. 1996 Feb;10(2):309-16 PubMed

Am J Physiol. 1998 Jun;274(6 Pt 1):C1429-52 PubMed

Nature. 1976 Mar 4;260(5546):78-90 PubMed

J Mol Med (Berl). 1999 Jan;77(1):107-10 PubMed

Biochem J. 1996 Dec 15;320 ( Pt 3):939-46 PubMed

J Rheumatol. 2000 Dec;27(12 ):2777-85 PubMed

Exp Cell Res. 2000 Jan 10;254(1):25-32 PubMed

Klin Wochenschr. 1979 Dec 3;57(23):1295-7 PubMed

Proc Assoc Am Physicians. 1997 Mar;109 (2):190-207 PubMed

J Neurochem. 1997 Nov;69(5):1890-6 PubMed

Physiol Res. 1995;44(2):79-86 PubMed

J Cell Sci. 1997 Apr;110 ( Pt 7):881-7 PubMed

J Clin Invest. 1991 Aug;88(2):493-9 PubMed

J Biol Chem. 2000 Nov 10;275(45):35584-91 PubMed

Scand J Gastroenterol Suppl. 1996;219:20-3 PubMed

PAR2: The Cornerstone of Pancreatic Diseases